GlassScriptPhysician profile
Brett R Hutton
NPI 1790996627
$11,799.50
in general payments reported to CMS, 2019-2025
24 companies · $1,653 in 2025
The $1,653 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,526 · 2020: $1,396 · 2021: $2,515 · 2022: $1,557 · 2023: $1,438 · 2024: $1,714 · 2025: $1,653.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,686 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,686.20 |
| Education | $118.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,178.42 | 2019-2025 | |
| Amgen INC. | $1,918.42 | 2019-2025 | Evenity, Prolia |
| Abbvie INC. | $1,763.46 | 2019-2025 | |
| Janssen Biotech, INC. | $1,501.26 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Ucb, INC. | $995.23 | 2019-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $977.72 | 2019-2025 | |
| Glaxosmithkline, LLC. | $752.48 | 2020-2025 | Benlysta, Nucala |
| Lilly USA, LLC | $423.66 | 2019-2023 | Taltz |
| Radius Health, INC. | $262.66 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $219.99 | 2019-2021 | |
| Genentech USA, INC. | $133.00 | 2019-2024 | Actemra |
| Pacira Therapeutics, INC. | $121.60 | 2019 | |
| Fresenius Kabi USA, LLC | $117.92 | 2023-2024 | Idacio |
| Horizon Therapeutics Plc | $81.53 | 2019-2022 | |
| Biosense Webster, INC. | $64.53 | 2023 | Carto 3 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $56.49 | 2024-2025 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.89 | 2023-2024 | Ofev, Cyltezo |
| Mallinckrodt Enterprises LLC | $47.65 | 2019 | |
| Sobi, INC | $39.42 | 2024 | |
| Sandoz INC. | $22.12 | 2024 | Hyrimoz |
| Kowa Pharmaceuticals America, INC. | $19.87 | 2025 | Zoryve |
| Sanofi-Aventis U.S. LLC | $19.02 | 2020 | |
| Mallinckrodt Hospital Products INC. | $14.37 | 2020 | |
| Organon LLC | $13.79 | 2025 | Hadlima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brett Hutton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.